Faster Care: Decentralized Antivenom Delivery

According to the PLOS Neglected Tropical Diseases article (Monteiro et al., 2026), decentralizing antivenom to Indigenous primary health poles increased timely treatment and reduced severe presentations and deaths.

• In the SAVING evaluation (March 2022–August 2025), 125 patients received decentralized care and 75.8% of them got antivenom within 6 hours of the bite, compared with 40.8% under usual care in the pre-intervention period (March 2017–February 2022), as reported in PLOS Neglected Tropical Diseases (2026).
• The PLOS Neglected Tropical Diseases (2026) article reports that mild envenomations on admission rose to 50.4% in the intervention group versus 32.7% pre-intervention, showing earlier presentation.
• The PLOS Neglected Tropical Diseases (2026) article documents 5 deaths (4.0%) in the usual-care cohort and 1 death (0.8%) in the intervention cohort during the evaluated periods, and reports only three mild early adverse reactions (2.4%) after decentralization.
• Monteiro et al., PLOS Neglected Tropical Diseases (2026) conclude: "Decentralized antivenom delivery within IHPs is an effective, safe, feasible and acceptable strategy, " and that "culturally adapted, decentralized care can be safely implemented in remote settings, with important implications for equitable health system strengthening."

The SAVING program placed antivenom and trained clinicians in accredited Indigenous Health Poles, and the PLOS Neglected Tropical Diseases (2026) article reports that this decentralization began implementation in 2022 and was evaluated through August 2025.

The PLOS Neglected Tropical Diseases (2026) study used a quasi-experimental pre-post design with surveillance data from SINAN, comparing March 2017–February 2022 (usual care) to March 2022–August 2025 (SAVING intervention) for 125 matched cases in each period.

The PLOS Neglected Tropical Diseases (2026) authors measured effectiveness by time to antivenom (≤6 hours), clinical severity at presentation, clinical complications during stay, case-fatality, and early adverse reactions, and they augmented those outcomes with semi-structured interviews conducted November 2024–August 2025 to assess implementation outcomes.

Decentralized antivenom delivery reduced treatment delays and severity at admission, according to the PLOS Neglected Tropical Diseases (2026) evaluation, and implementers should prioritize readiness checks, culturally adapted protocols, and competency-based training as described in the SAVING rollout.

The PLOS Neglected Tropical Diseases (2026) article shows that qualitative interviews (November 2024–August 2025) captured acceptability, appropriateness, and feasibility, demonstrating that mixed-methods implementation research gives actionable context beyond surveillance numbers.

Implementation scientists should note the PLOS Neglected Tropical Diseases (2026) finding that interoperability gaps between Indigenous health systems and national surveillance (SIASI vs SINAN) increased workload and hampered monitoring, an issue to track during scale-up.

Ethics note: this blog summarizes research findings for program and research purposes and is not clinical guidance; the PLOS Neglected Tropical Diseases (2026) study followed CONEP ethical approvals and local Indigenous consent procedures.

The PLOS Neglected Tropical Diseases (2026) SAVING evaluation shows that decentralized antivenom delivery improved timely treatment, reduced severity at admission, and was acceptable and safe in Indigenous primary care settings.

Researchers and implementers should combine surveillance metrics with qualitative implementation outcomes to guide scale-up decisions, as Monteiro et al. did in the SAVING program.

If your team runs mixed-methods evaluations or needs to synthesize multilingual interviews and surveillance spreadsheets, AI-enabled qualitative tools can shorten analysis timelines and produce actionable outputs for policy makers.

To test AI-enabled qualitative workflows on your implementation data, Try Evidano for free.